肥胖者接种COVID-19疫苗有效:美国肥胖学会立场声明
美国肥胖学会针对肥胖者接种SARS-CoV-2疫苗有效性的疑问发布立场声明,批判性评估已发表同行评议文献及辉瑞-BioNTech、Moderna、强生紧急使用授权申请简报文件。结论为这些疫苗高度有效,基于发表时可得科学证据,肥胖与无肥胖者间有效性无显著差异。学会认为因3期试验设计、结局指标、剂次间隔及地区变异株差异,无法确定三种疫苗中哪种对任一重量亚人群“最佳”。所有三项试验均显示对COVID-19相关住院和死亡高度有效,故鼓励≥18岁肥胖成人(辉瑞-BioNTech为≥16岁)尽早接种美国FDA紧急使用授权的任一现有疫苗。
要点
- 美国肥胖学会结论:现有COVID-19疫苗在肥胖者中高度有效,且肥胖与无肥胖者间有效性无显著差异。
- 三项试验均显示对COVID-19相关住院和死亡高度有效。
- 因试验设计、结局指标、剂次间隔及地区变异株差异,无法确定三种疫苗中哪种对任一重量亚人群最佳。
- 学会鼓励≥18岁肥胖成人(辉瑞-BioNTech为≥16岁)尽早接种美国FDA紧急使用授权的任一现有疫苗。
适用人群与场景
- 肥胖成人,年龄≥18岁(辉瑞-BioNTech疫苗为≥16岁)。
处置流程与药物剂量
- 美国肥胖学会鼓励≥18岁肥胖成人(辉瑞-BioNTech为≥16岁)尽早接种美国FDA紧急使用授权的任一现有COVID-19疫苗。
研究设计与关键结果
- 美国肥胖学会批判性评估已发表同行评议文献及辉瑞-BioNTech、Moderna、强生紧急使用授权申请简报文件后得出结论:这些疫苗高度有效,基于发表时可得科学证据,肥胖与无肥胖者间有效性无显著差异。
- 学会认为因3期试验设计、结局指标、剂次间隔及地区SARS-CoV-2变异株存在差异(如强生试验中的南非B.1.351),无法确定三种疫苗中哪种对任一重量亚人群“最佳”。
- 所有三项试验均显示对COVID-19相关住院和死亡高度有效。
证据类型、等级与局限
- 证据类型:学会立场声明,基于已发表同行评议文献及三种疫苗紧急使用授权申请简报文件的批判性评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 美国肥胖学会鼓励≥18岁肥胖成人(辉瑞-BioNTech为≥16岁)尽早接种美国FDA紧急使用授权的任一现有COVID-19疫苗。
指南或共识出处
- 美国肥胖学会(The Obesity Society)立场声明,发表于Obesity (Silver Spring)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The position statement is issued by The Obesity Society in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policy makers, and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV-2, the virus that causes COVID-19. The Obesity Society has critically evaluated data from published peer-reviewed literature and briefing documents from Emergency Use Authorization applications submitted by Pfizer-BioNTech, Moderna, and Johnson & Johnson. We conclude that these vaccines are highly efficacious, and their efficacy is not significantly different in people with and without obesity, based on scientific evidence available at the time of publication. The Obesity Society believes there is no definitive way to determine which of these three COVID-19 vaccines is "best" for any weight subpopulation (because of differences in the trial design and outcome measures in the phase 3 trials, elapsed time between doses, and regional differences in the presence of SARS-CoV-2 variants [e.g., South Africa B.1.351 in Johnson & Johnson trial]). All three trials have demonstrated high efficacy against COVID-19-associated hospitalization and death. Therefore, The Obesity Society encourages adults with obesity ≥18 years (≥16 years for Pfizer-BioNTech) to undergo vaccination with any one of the currently available vaccines authorized for emergency use by the US Food and Drug Administration as soon as they are able.
参考来源
- Butsch WS, Hajduk A, Cardel MI, et al. COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society. Obesity (Silver Spring). 2021. PMID: 34212511. doi:10.1002/oby.23251
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。